YaoGeJu

Company directoryChina company filings

Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference e1ea325efb

Complete CDE snapshot
2026/11/13 06:42
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.

Drug filings

11 acceptance records as first applicant, grouped into 8 source drug names. Source data as of 2026/11/13 06:42.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Edaravone and Dexborneol Concentrated Solution for Injection 1 records · Latest accepted 2026/04/17

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600891Generic2026/04/17Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
Finerenone Tablets 2 records · Latest accepted 2025/10/29

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2503826Generic2025/10/29Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized; Jiangsu Cheng Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2503825Generic2025/10/29Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized; Jiangsu Cheng Kang Pharma Co., Ltd. romanizedCDE ↗
Minocycline Hydrochloride Tablets 1 records · Latest accepted 2024/04/12

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2450232Supplement2024/04/12Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
Dobutamine Hydrochloride Injection 1 records · Latest accepted 2023/10/24

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2350783Supplement2023/10/24Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
Cisatracurium Besylate Injection 2 records · Latest accepted 2023/07/08

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2301843Generic2023/07/08Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHS2301842Generic2023/07/08Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
Urapidil Hydrochloride Injection 1 records · Latest accepted 2022/05/20

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200736Generic2022/05/20Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
Palonosetron Hydrochloride Injection 1 records · Latest accepted 2022/05/12

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2250280Supplement2022/05/12Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
Parecoxib Sodium for Injection 2 records · Latest accepted 2022/02/21

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200344Generic2022/02/21Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHS2200343Generic2022/02/21Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

3 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Edaravone and Dexborneol Concentrated Solution for Injection CYHS2600891Generic2026/04/17Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
Finerenone Tablets CYHS2503826Generic2025/10/29Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized; Jiangsu Cheng Kang Pharma Co., Ltd. romanizedCDE ↗
Finerenone Tablets CYHS2503825Generic2025/10/29Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized; Jiangsu Cheng Kang Pharma Co., Ltd. romanizedCDE ↗

Catalogue holder records

10 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Minocycline Hydrochloride TabletsWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedWuxi Kai Fu Pharmaceutical Co., Ltd. romanized国药准字H200448472025/08/08Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Cisatracurium Besylate InjectionWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedWuxi Kai Fu Pharmaceutical Co., Ltd. romanized国药准字H202493552024/11/15Generic approved under the new chemical-drug registration classificationCDE ↗
Cisatracurium Besylate InjectionWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedWuxi Kai Fu Pharmaceutical Co., Ltd. romanized国药准字H202493542024/11/15Generic approved under the new chemical-drug registration classificationCDE ↗
Dobutamine Hydrochloride InjectionWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedWuxi Kai Fu Pharmaceutical Co., Ltd. romanized国药准字H202472652024/11/04Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Palonosetron Hydrochloride InjectionWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedWuxi Kai Fu Pharmaceutical Co., Ltd. romanized国药准字H202031292024/03/15Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Urapidil Hydrochloride InjectionWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedWuxi Kai Fu Pharmaceutical Co., Ltd. romanized国药准字H202345192023/11/21Generic approved under the new chemical-drug registration classificationCDE ↗
Parecoxib Sodium for InjectionWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedWuxi Kai Fu Pharmaceutical Co., Ltd. romanized国药准字H202344892023/11/14Generic approved under the new chemical-drug registration classificationCDE ↗
Parecoxib Sodium for InjectionWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedWuxi Kai Fu Pharmaceutical Co., Ltd. romanized国药准字H202344712023/11/14Generic approved under the new chemical-drug registration classificationCDE ↗
Apixaban TabletsWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedWuxi Kai Fu Pharmaceutical Co., Ltd. romanized国药准字H202237812022/11/01Not stated by sourceCDE ↗
Pantoprazole Sodium For InjectionWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedWuxi Kai Fu Pharmaceutical Co., Ltd. romanized国药准字H200837002021/10/28Drug that passed quality-and-efficacy consistency evaluationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

5 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.

NameCompany / applicantRegistration numberStatusSource update dateView source
茴拉西坦 · No verified English nameWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedY20190006180A2025/09/06CDE ↗
莫海林 · No verified English nameWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedY20190004377A2025/07/04CDE ↗
盐酸氯普鲁卡因 · No verified English nameWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedY20190004373A2025/07/09CDE ↗
七叶皂苷钠 · No verified English nameWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedY20190004355A2025/05/31CDE ↗
泛酸钠 · No verified English nameWuxi Kai Fu Pharmaceutical Co., Ltd. romanizedY20190004346A2025/07/10CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

3 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Tranexamic Acid Injection CYHS2401802Generic2024/06/14Zhejiang Xiong Di Pharma Co., Ltd. romanized; Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
Esomeprazole Sodium for Injection CYHB2201057Supplement2022/06/29Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized; Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
Esomeprazole Sodium for Injection CYHB2201056Supplement2022/06/29Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized; Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39
Full API register
Last successful update: 2026/11/13 06:41
NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.